Ulipristal acetate – a review of the new therapeutic indications and future prospects

ABSTRACT

Uterine leiomyomata (ULM) are benign smooth muscle neoplasms that are hormonedependent. Menorrhagia and anemia are the most common symptoms associated with this disorder. As many as 200000 cases of ULM per year are registered in the USA, and hysterectomy remains the major therapeutic option for treatment. Because gonadal hormones induce or maintain leiomyoma growth, selective progesterone receptor modulators have been evaluated as suitable therapeutic agents. Ulipristal acetate (UPA) is a therapeutic agent used as an emergency contraceptive agent. The therapeutic spectrum of the agent has been expanded by a new indication at the end of 2012. Based on two large-scale international randomized trials (PEARL I and PEARL II), UPA (Esmya tab. 5 mg) received European approval for preoperative treatment of ULM in the spring of 2012. The drug is indicated for treatment of moderate to severe symptoms of uterine fibroids. The duration of the treatment with UPA is limited to no more than 3 months when it is used to reduce the size of the tumor, to stop or reduce bleeding and to increase the red blood count prior to surgery. A disadvantage of the cited studies is that the course of treatment is limited to 3 months. Therefore, more data are needed regarding the benefits and risks of long-term treatment with UPA.

The use of UPA in some forms of hypermenorrhoea is discussed as a future therapeutic option but the data are not yet conclusive.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management.Obstet Gynecol 2004;104(2):393-406.

  • 2. Jacoby VL, Fujimoto VY, Giudice LC, et al. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 2010;202(6):514-21.

  • 3. Evans P, Brunsell S. Uterine fi broid tumors: diagnosis and treatment. Am Fam Physician 2007;75:1503-8.

  • 4. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133-7.

  • 5. Van Voorhis B. A 41-year-old woman with menorrhagia, anemia, and fi broids: review of treatment of uterine fi broids. JAMA 2009;301:82-93.

  • 6. Collins J, Crosignani PG. Endometrial bleeding.Hum Reprod Update 2007;13:421-31.

  • 7. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008;90:5 Suppl:S125-30.

  • 8. Somigliana E, Vercellini P, Daguati R, et al. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007;13:465-76.

  • 9. Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006;33:145-52.

  • 10. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424-30.

  • 11. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fi broids. Cochrane Database Syst Rev 2001;CD000547.

  • 12. Donnez J, Schrurs B, Gillerot S, et al. Treatment of uterine fi broids with implants of gonadotropinreleasing hormone agonist: assessment by hysterography.Fertil Steril 1989;51:947-50.

  • 13. Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod 1999;14:44-8.

  • 14. Dubuisson JB, Fauconnier A, Fourchotte, et al.Laparoscopic myomectomy: predicting the risk conversion to an open procedure. Hum Reprod 2001;16:1726-31.

  • 15. Rossetti A, Sizzi O, Soranna L, et al. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy.Hum Reprod 2001;16:770-4.

  • 16. Scialli AR, Jestila KJ. Sustained benefi ts of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril 1995;64:313-20.

  • 17. Yin P, Lin Z, Reierstad S, et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010;70:1722-30.

  • 18. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23.

  • 19. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012;358(2):223-231.

  • 20. Zapata LB, Whiteman MK, Tepper NK, et al.Intrauterine device use among women with uterine fi broids: a systematic review. Contraception 2010;82:41-55.

  • 21. Mara, Michal, et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fi broid embolization and myomectomy. Cardiovascular and interventional radiology 31.1 (2008): 73-85.

  • 22. Nieman LK, Blocker W, Nansel T, et al. Effi cacy and tolerability of CDB-2914 treatment for symptomatic uterine fi broids: a randomized, double-blind, placebocontrolled, phase IIb study. Fertil Steril 2011;95:767.e1-772.e1.

  • 23. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307.

  • 24. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981-93.

  • 25. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic- pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92(9):3582-9.

  • 26. Attardi BJ, Burgenson J, Hild SA, et al. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188:111-23.

  • 27. Eric D. Levens, Clariss Potlog-Nahari, еt al.CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111(5):1129-36.

  • 28. Donnez J, Tatarchuk TF, Bouchard F, et al. Ulipristal acetate versus placebo for fi broid treatment before surgery. N Engl J Med 2012;366(5):409-20.

  • 29. Croxtall JD. Ulipristal acetate: in uterine fi broids.Drugs 2012;72(8):1075-85.

  • 30. Donnez J, et al. Ulipristal acetate versus leuprolide acetate for uterine fi broids. PEARL II Study Group.N Engl J Med 2012;366:421-32.

  • 31. Musallam KM, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011;378(9800):1396-407.

  • 32. De Falco M, et al. Leiomyoma pseudo-capsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol 2009;144:44-7.

  • 33. BDA.bg [Internet]. Sofi a: Bulgarian Drug Agency: http://en.bda.bg/ (2012) Available.

  • 34. EMA.eu. [Internet]. London: European Medicines Agency. Esmya- Product information (2012) EMEA/H/C/002041-IB/09. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002041/human_med_001542.jsp&mid=WC0b01ac058001d124. Available.

  • 35. Rabe T, Albring C, Bitzer J, еt al. Ulipristal acetate for treatment of symptomatic uterine fi broids and myoma-related hypermenorrhea. J Reproduktionsmed Endokrinol 2012;9(2):106-26

Journal + Issues

Search